ଏର୍ଗୋଟାମାଇନ

ଏର୍ଗୋଟାମାଇନ
Clinical data
Trade names	Alone: Ergomar, others; With caffeine: Cafergot, others
Synonyms	2'-Methyl-5'α-benzyl-12'-hydroxy-3',6',18-trioxoergotaman; 9,10α-Dihydro-12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione
AHFS/Drugs.com	monograph
Pregnancy; category	US: X ;
Routes of; administration	By mouth, under the tongue
Legal status
Legal status	AU: S4 (Prescription only) ; CA: Schedule VI ; UK: POM (Prescription only) ; US: ℞-only DEA controlled precursor;
Pharmacokinetic data
Bioavailability	Intravenous: 100%, ; Intramuscular: 47%,; By mouth: <1% (Enhanced by co-administration of caffeine)
Metabolism	Liver
Elimination half-life	2 hours
Excretion	90% biliary
Identifiers
	IUPAC name (6aR,9R)-N-((2R,5S,10aS,10bS)-5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide;
ECHA InfoCard	100.003.658
Chemical and physical data
Formula	C33H35N5O5
Molar mass	୫୮୧.୬୭ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;
	InChI InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1 ; Key:XCGSFFUVFURLIX-VFGNJEKYSA-N ;
(verify)

ଏର୍ଗୋଟାମାଇନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏହାର ଏକ ବେପାର ନାମ ଏର୍ଗୋମାର, ଏକ ଔଷଧ ଯାହା ଅଧକପାଳି, କ୍ଲଷ୍ଟର ମୁଣ୍ଡ ବିନ୍ଧା ଏବଂ ପ୍ରସବପର ରକ୍ତସ୍ରାବର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ^[୬] ଚାପଗ୍ରସ୍ତ ମୁଣ୍ଡବିନ୍ଧା ପାଇଁ ଏହା ପ୍ରଭାବଶାଳୀ ନୁହେଁ ।^[୨] ଏହା ପାଟିରେ, ଜିଭ ତଳେ କିମ୍ବା ମଳଦ୍ୱାର ବାଟେ ଦିଆଯାଏ ।^[୨] ^[୭] ଔଷଧର ପ୍ରଭାବ ସାଧାରଣତଃ ୩୦ ମିନିଟରୁ ୨ ଘଣ୍ଟା ମଧ୍ୟରେ ଆରମ୍ଭ ହୁଏ ।^[୮]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବାନ୍ତି, ପେଟ ଯନ୍ତ୍ରଣା ଏବଂ ଅବୟବ ଅଗ୍ରଭଗରେ ଝିମଝିମ ହୁଏ ।^[୨] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅପବ୍ୟବ‌ହାର ମୁଣ୍ଡ ବିନ୍ଧା, ଫୁସଫୁସ ଫାଇବ୍ରୋସିସ୍ ଏବଂ ଏର୍ଗୋଟିଜ୍ମ ଆରମ୍ଭ ହୋଇପାରେ । ^[୯]^[୨] ଗର୍ଭାବସ୍ଥା କିମ୍ବା ସ୍ତନ୍ୟପାନ ସମୟରେ ବ୍ୟବ‌ହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ | ^[୧] ଭାସ୍କୁଲାର ରୋଗ, ଯକୃତ କିମ୍ବା ବୃକ୍‌କ ସମସ୍ୟା ଥିଲେ ଏହା ସୁପାରିଶ କରାଯାଏ ନାହିଁ ।^[୯] ଏହା ଏରଗଟ୍ ପରିବାରର ଏକ ଔଷଧ ଅଛି ଏବଂ ଅନ୍ୟାନ୍ୟ ରିସେପ୍ଟରମାନଙ୍କ ଭଳି ସେରୋଟୋନିନ୍ ଉପରେ କାର୍ଯ୍ୟ କରିଥାଏ ।^[୯] ^[୮]

ଆର୍ଥର୍ ଷ୍ଟୋଲ୍ ୧୯୧୮ ମସିହାରେ ପ୍ରଥମେ ଏର୍ଗଟ୍ କବକଠାରୁ ଏର୍ଗୋଟାମାଇନ ବିଚ୍ଛିନ୍ନ କରିଥିଲେ ।^[୧୦] ଅନ୍ତତଃ ପକ୍ଷେ ଷୋଡଶ ଶତାବ୍ଦୀରୁ ପ୍ରସବ କରେଇବା ପାଇଁ, ଗର୍ଭପାତ କରେଇବା ପାଇଁ ଓ ପ୍ରସବପର ରକ୍ତସ୍ରାବ ଚିକିତ୍ସା ପାଇଁ ଏହି କବକ ଔଷଧ ଭାବରେ ବ୍ୟବହୃତ ହେଉଥିଲା ।^[୧୧] ଟ୍ରିପଟାନ୍ସ ପ୍ରଭାବଶାଳୀ ନ ହେଲେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ସାଧାରଣତଃ ବ୍ୟବହୃତ ହୁଏ ଯଦିଓ ଦୁନିଆର କେତେକ ସ୍ଥାନରେ ସାଧାରଣ ଭାବରେ ବ୍ୟବହୃତ ହୁଏ | ^[୯] ଏହା ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ କେଫିନ ସ‌ହିତ ଏହା କାଫେରଗଟ୍ ନାମରେ ଉପଲବ୍ଧ ।^[୨]

ଆଧାର

1 2 "Ergotamine (Ergomar) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 25 November 2020. Retrieved 23 July 2021.
1 2 3 4 5 6 7 "Ergotamine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 23 July 2021.
1 2 Sanders SW, Haering N, Mosberg H, Jaeger H (1986). "Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing". European Journal of Clinical Pharmacology. 30 (3): 331–4. doi:10.1007/BF00541538. PMID 3732370. S2CID 37538721.
1 2 3 4 Tfelt-Hansen P, Johnson ES (1993). "Ergotamine". In Olesen J, Tfelt-Hansen P, Welch KM (eds.). The Headaches. New York: Raven Press. pp. 313–22.
↑ Ibraheem JJ, Paalzow L, Tfelt-Hansen P (December 1983). "Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers". British Journal of Clinical Pharmacology. 16 (6): 695–9. doi:10.1111/j.1365-2125.1983.tb02243.x. PMC 1428366. PMID 6419759.
↑ Weeks, A (January 2015). "The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to next?". BJOG : An International Journal of Obstetrics and Gynaecology. 122 (2): 202–10. doi:10.1111/1471-0528.13098. PMID 25289730.
↑ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 500. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
1 2 Aschenbrenner, Diane S.; Venable, Samantha J. (2009). Drug Therapy in Nursing (in ଇଂରାଜୀ). Lippincott Williams & Wilkins. p. 423. ISBN 978-0-7817-6587-9. Archived from the original on 2021-08-28. Retrieved 2021-07-23.
1 2 3 4 Levin, Morris (8 May 2008). Comprehensive Review of Headache Medicine (in ଇଂରାଜୀ). Oxford University Press, USA. p. 217. ISBN 978-0-19-536673-0. Archived from the original on 28 August 2021. Retrieved 23 July 2021.
↑ Silberstein, Stephen D. (8 May 2018). Headache in Clinical Practice (in ଇଂରାଜୀ). Routledge. p. PT19. ISBN 978-1-351-44131-5. Archived from the original on 28 August 2021. Retrieved 23 July 2021.
↑ Nielsch, Ulrich; Fuhrmann, Ulrike; Jaroch, Stefan (30 March 2016). New Approaches to Drug Discovery (in ଇଂରାଜୀ). Springer. p. PA6. ISBN 978-3-319-28914-4. Archived from the original on 28 August 2021. Retrieved 23 July 2021.

[Preg2021-1] 1 2 "Ergotamine (Ergomar) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 25 November 2020. Retrieved 23 July 2021.

[AHFS2021-2] 1 2 3 4 5 6 7 "Ergotamine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 23 July 2021.

[kinetics1-3] 1 2 Sanders SW, Haering N, Mosberg H, Jaeger H (1986). "Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing". European Journal of Clinical Pharmacology. 30 (3): 331–4. doi:10.1007/BF00541538. PMID 3732370. S2CID 37538721.

[kinetics2-4] 1 2 3 4 Tfelt-Hansen P, Johnson ES (1993). "Ergotamine". In Olesen J, Tfelt-Hansen P, Welch KM (eds.). The Headaches. New York: Raven Press. pp. 313–22.

[pmid6419759-5] Ibraheem JJ, Paalzow L, Tfelt-Hansen P (December 1983). "Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers". British Journal of Clinical Pharmacology. 16 (6): 695–9. doi:10.1111/j.1365-2125.1983.tb02243.x. PMC 1428366. PMID 6419759.

[Week2015-6] Weeks, A (January 2015). "The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to next?". BJOG : An International Journal of Obstetrics and Gynaecology. 122 (2): 202–10. doi:10.1111/1471-0528.13098. PMID 25289730.

[BNF80-7] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 500. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[Asc2009-8] 1 2 Aschenbrenner, Diane S.; Venable, Samantha J. (2009). Drug Therapy in Nursing (in ଇଂରାଜୀ). Lippincott Williams & Wilkins. p. 423. ISBN 978-0-7817-6587-9. Archived from the original on 2021-08-28. Retrieved 2021-07-23.

[Lev2008-9] 1 2 3 4 Levin, Morris (8 May 2008). Comprehensive Review of Headache Medicine (in ଇଂରାଜୀ). Oxford University Press, USA. p. 217. ISBN 978-0-19-536673-0. Archived from the original on 28 August 2021. Retrieved 23 July 2021.

[10] Silberstein, Stephen D. (8 May 2018). Headache in Clinical Practice (in ଇଂରାଜୀ). Routledge. p. PT19. ISBN 978-1-351-44131-5. Archived from the original on 28 August 2021. Retrieved 23 July 2021.

[11] Nielsch, Ulrich; Fuhrmann, Ulrike; Jaroch, Stefan (30 March 2016). New Approaches to Drug Discovery (in ଇଂରାଜୀ). Springer. p. PA6. ISBN 978-3-319-28914-4. Archived from the original on 28 August 2021. Retrieved 23 July 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]